AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00865917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I(f)-blocker (ivabradine)
Description: ivabradine 7.5 mg once per day
Study NCT00865917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching appearance
Study NCT00702442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: 0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
Study NCT00702442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution administrated i.v 30 min prior surgery
Study NCT03030105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: placebo
Study NCT00382590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Azacytidine
Description: 75 mg/m\^2 daily for 7 days (days 1-7) via subcutaneous injection.
Study NCT00382590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: 20 mg twice daily via subcutaneous injection for 10 days.
Study NCT00382590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid (VPA)
Description: 50 mg/m\^2 orally daily days 1-7.
Study NCT00591617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment plus Suboxone pharmacotherapy
Description: Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
Study NCT04188015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5mg ANX007
Description: A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
Study NCT04188015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5.0mg ANX007
Description: A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
Study NCT04188015 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.
Study NCT00559403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STD Risk-Reduction
Description: Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
Study NCT00559403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Description: The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
Study NCT02260869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve radiofrequency ablation
Description: Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
Study NCT02260869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pain Management Radiofrequency Kit
Description: The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
Study NCT01122407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: L-NMMA 250 ug/Kg/min
Study NCT01122407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Will infuse trimethaphan for until complete autonomic blockade is achieved.
Study NCT00834639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium
Description: delayed-release 500 mg tablet
Study NCT00834639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote®
Description: delayed-release 500 mg tablet
Study NCT03653351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 mA (current density = 0.57 A/m2) and will be applied for approximately 30 minutes per day during meditative practices of the MBSR protocol.
Study NCT03653351 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 milliampere (mA) (current density = 0.57 A/m2), however, the device is pre-programmed to turn off after 1 minute of active stimulation (and then turn back on briefly at the end of the 30 minutes).
Study NCT02814227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zansors® sleep screening device
Description: Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
Study NCT00177307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
Study NCT00177307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
Study NCT00177307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
Study NCT04346901 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thiamazol
Description: All new hyperthyroid with melasma patients were recruited and their mMASI were calculated All subjects were given thiamazole by Internist based on their clinical hyperthyroidism After 3 months of taking hyperthyroid drugs (thiamazole), mMASI were recalculated and compared
Study NCT03030105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine 0.6 MG/ML
Description: cognition impairment
Study NCT03030105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 MG/ML
Description: cognition impairment
Study NCT03030105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine 0.6 MG/ML
Description: cognition impairment
Study NCT03030105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine placebo
Description: placebo
Study NCT01042145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 2 mgs/kg for 3 days
Study NCT01042145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.6 mgs for one day, then placebo for 2 days
Study NCT00003829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00102648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Given PO
Study NCT00102648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02223650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overminus treatment
Description: 2.50D overminus spectacles
Study NCT00493337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compliance Card
Study NCT01820533 — intervention group
Intervention type: OTHER
Intervention: Cell Phone Survey
Description: Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
Study NCT04093141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IRE
Description: in situ irreversible electroporation
Study NCT02115997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
Study NCT02115997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day \[mg/kg/day\]) at the discretion of investigator given daily until participants are off the drug.
Study NCT02115997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at 375 milligrams per meter square (mg/m\^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
Study NCT01676025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRA
Study NCT01676025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LA
Study NCT03519698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Warm water
Description: Footbaths were prepared with 12 liters of warm water (40 °C)
Study NCT03519698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water
Description: Footbaths were prepared with 12 liters of warm water (40 °C)
Study NCT03519698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mustard
Description: 12 l footbath with warm water (40 °C) and 80 g mustard flour (Sinapis nigrea semen plv.)
Study NCT03519698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger
Description: 12 l footbath with warm water (40 °C) and 80 g ginger flour (Zingiberis rhizoma plv.)
Study NCT03343405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mind/Body Program for Fertility
Description: The Mind/Body intervention involves (1) reducing physical symptoms of stress, (2) enhancing lifestyle behaviors related to fertility, (4) self-nurturing and coping skills, and (5) relaxation methods.
Study NCT03499626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD
Study NCT01465503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR \<30 ml/min/1.73 m2.
Study NCT01465503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unfractionated Heparin
Description: Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
Study NCT01231503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's Investigational Malaria Vaccine 257049
Description: 3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=\<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =\< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
Study NCT01231503 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: 1 dose, intramuscular route: left antero-lateral thigh at birth (=\< 7 days of age)
Study NCT01231503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: 1 dose, intramuscular route: left antero-lateral thigh at birth (=\< 7 days of age)
Study NCT01231503 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix HepB Hib
Description: 3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
Study NCT01231503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix HepB Hib
Description: 3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
Study NCT02223650 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-overminus treatment
Description: spectacles without overminus or no spectacles
Study NCT03376451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of endometrium and blood biomarkers for endometriosis diagnosis
Description: Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
Study NCT03760367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue covarine toothpaste
Description: 2 min toothbrushing with 1 g of Pepsodent White Now Gold
Study NCT03760367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control toothpaste
Description: 2 min toothbrushing with 1 g of Colgate Advanced Whitening
Study NCT00962975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
Study NCT00862342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
Study NCT01828541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Patients in this group will receive standard care plus 4 sessions of hypnosis.
Study NCT01828541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Study NCT04501978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: Participants are no longer being randomized to this intervention.
Study NCT04501978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion
Study NCT04501978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Provided to all study participants as SOC unless contraindicated for an individual patient.
Study NCT04501978 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Provided to all study participants as SOC unless contraindicated for an individual patient.
Study NCT04501978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-7831
Description: Participants are no longer being randomized to this intervention.
Study NCT04501978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-196/BRII-198
Description: Participants are no longer being randomized to this intervention.
Study NCT04501978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: Participants are no longer being randomized to this intervention.
Study NCT04501978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0420
Description: Participants are no longer being randomized to this intervention.
Study NCT04501978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: 250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.
Study NCT03087422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message intervention
Description: The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
Study NCT03737500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Lite® light weight breast implant
Description: Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant
Study NCT03737500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard silicone-based breast implant
Description: Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution
Study NCT01609634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test Product
Description: Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
Study NCT05360342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K supplement
Description: Single dose of vitamin K supplement
Study NCT03467997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trier social stress test
Description: Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.
Study NCT03467997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel exhaust
Description: Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
Study NCT01609634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Product 1
Description: Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
Study NCT01609634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Product 2
Description: Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
Study NCT04270864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 20mg (4mL) IT
Study NCT04270864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360mg IV then 480mg IV
Study NCT04270864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: 8 mg (2mL) IT
Study NCT05367817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise therapy
Description: Participants perform specific neuromuscular exercises aimed at enhancing the sensorimotor control of the wrist.
Study NCT05367817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training program
Description: Participants perform range of motion exercises for the wrist.
Study NCT04430231 — intervention group
Intervention type: OTHER
Intervention: Wait list time